Cite
Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
MLA
Giugliani, Roberto, et al. “Neurocognitive and Somatic Stabilization in Pediatric Patients with Severe Mucopolysaccharidosis Type I after 52 Weeks of Intravenous Brain-Penetrating Insulin Receptor Antibody-Iduronidase Fusion Protein (Valanafusp Alpha): An Open Label Phase 1-2 Trial.” Orphanet Journal of Rare Diseases, vol. 13, no. 1, July 2018, p. 110. EBSCOhost, https://doi.org/10.1186/s13023-018-0849-8.
APA
Giugliani, R., Giugliani, L., de Oliveira Poswar, F., Donis, K. C., Corte, A. D., Schmidt, M., Boado, R. J., Nestrasil, I., Nguyen, C., Chen, S., & Pardridge, W. M. (2018). Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. Orphanet Journal of Rare Diseases, 13(1), 110. https://doi.org/10.1186/s13023-018-0849-8
Chicago
Giugliani, Roberto, Luciana Giugliani, Fabiano de Oliveira Poswar, Karina Carvalho Donis, Amauri Dalla Corte, Mathias Schmidt, Ruben J Boado, et al. 2018. “Neurocognitive and Somatic Stabilization in Pediatric Patients with Severe Mucopolysaccharidosis Type I after 52 Weeks of Intravenous Brain-Penetrating Insulin Receptor Antibody-Iduronidase Fusion Protein (Valanafusp Alpha): An Open Label Phase 1-2 Trial.” Orphanet Journal of Rare Diseases 13 (1): 110. doi:10.1186/s13023-018-0849-8.